Everolimus

Novartis offloads phase 2 mTORC1 programs to PureTech

Novartis has offloaded two midphase mTORC1 inhibitors to PureTech Health in return for an equity stake and a source of future milestones and royalties.

Nick Paul Taylor Mar 24, 2017 4:24am